Published in Oncotarget on March 21, 2017
Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev (2005) 9.62
Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev (2005) 4.65
Biological roles of fibroblast growth factor-2. Endocr Rev (1997) 3.57
"Diabodies": small bivalent and bispecific antibody fragments. Proc Natl Acad Sci U S A (1993) 2.91
A signaling pathway leading to metastasis is controlled by N-cadherin and the FGF receptor. Cancer Cell (2002) 2.88
Fibroblast growth factors and their receptors in cancer. Biochem J (2011) 2.66
Akt regulates cell survival and apoptosis at a postmitochondrial level. J Cell Biol (2000) 1.83
A recombinant immunotoxin containing a disulfide-stabilized Fv fragment. Proc Natl Acad Sci U S A (1993) 1.35
Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo. Oncoimmunology (2012) 1.14
Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide stabilization of the Fv fragment. J Biol Chem (1994) 1.14
Monoclonal antibodies against heparin-binding growth factor II/basic fibroblast growth factor that block its biological activity: invalidity of the antibodies for tumor angiogenesis. Proc Natl Acad Sci U S A (1989) 1.12
Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv. Protein Eng (1994) 1.07
Development of a humanized disulfide-stabilized anti-p185HER2 Fv-beta-lactamase fusion protein for activation of a cephalosporin doxorubicin prodrug. Cancer Res (1995) 0.90
CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients. Gynecol Oncol (2004) 0.88
Expression, purification and structural characterization of functionally replete thrombospondin-1 type 1 repeats in a bacterial expression system. Protein Expr Purif (2011) 0.87
PD-ECGF, bFGF, and VEGF expression in non-small cell lung carcinomas and their association with lymph node metastasis. Anticancer Res (1999) 0.86
Disulfide-stabilized diabody antiCD19/antiCD3 exceeds its parental antibody in tumor-targeting activity. Cell Oncol (Dordr) (2012) 0.86
Expression of vascular endothelial growth factor and basic fibroblast growth factor in small adenocarcinomas. Oncol Rep (2001) 0.83
Selection and characterization of a human neutralizing antibody to human fibroblast growth factor-2. Biochem Biophys Res Commun (2010) 0.82
Monoclonal antibodies targeting basic fibroblast growth factor inhibit the growth of B16 melanoma in vivo and in vitro. Oncol Rep (2010) 0.81
Effect of intraperitoneally, intravenously and intralesionally administered monoclonal anti-beta-FGF antibodies on rat chondrosarcoma tumor vascularization and growth. Anticancer Res (1997) 0.81
Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: preliminary study. Hybridoma (2001) 0.81
Soluble production and function of vascular endothelial growth factor/basic fibroblast growth factor complex peptide. Biotechnol Prog (2014) 0.80
MicroRNA-126 Targeting PIK3R2 Inhibits NSCLC A549 Cell Proliferation, Migration, and Invasion by Regulation of PTEN/PI3K/AKT Pathway. Clin Lung Cancer (2016) 0.80
[Inhibition of angiogenesis and growth of malignant gliomas in the athymic nude rat model: immunotherapy against "basic fibroblast growth factor"]. Zentralbl Neurochir (1996) 0.80